Inverness Gets Financial Backing from GE Capital, UBS in Biosite Bid
 
Biosite said last week that Inverness Medical Innovations plans to buy the company with financial backing from General Electric Capital Corporation and UBS Loan Finance and Securities.
 
In a revised commitment letter Inverness sent to Biosite and disclosed last week, Biosite said that GECC and UBSS would loan Inverness $1.3 billion. GECC will provide 40 percent of the amount and UBSS will drum up the 60 percent balance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.